Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Bio Behavioral Health

Neither a doctor nor a teaching hospital

Research payments

$8,419,154

385 payments

Through program year 2025, Bio Behavioral Health is reported as receiving $8,419,154 in research payments, across 385 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $517,861 65
2024 Research $2,284,158 15
2023 Research $1,556,609 33
2022 Research $661,997 29
2021 Research $1,561,715 65
2020 Research $1,047,942 84
2019 Research $788,873 94

Breakdown

Who paid Research payments · program years 2019–2025
  1. BioXcel Therapeutics, Inc. $3,396,931 13 payments
  2. Eli Lilly and Company $1,631,828 49 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,248,656 15 payments
  4. Allergan Inc. $776,408 115 payments
  5. AbbVie, Inc. $768,145 68 payments
  6. Eisai Inc. $246,714 63 payments
  7. Amgen Inc. $108,698 12 payments
  8. ITI, Inc. $106,077 29 payments
  9. ACADIA Pharmaceuticals Inc $72,979 12 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $36,704 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of Bxcl501 Over A 12 Week Period in Subjects With Agitation Associated With Dementia $1,907,720 8 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $848,678 5 payments
  3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy Andsafety Study of PRN Dosing of Bxcl501 Over A 12 Week Treatment Period Insubjects With Agitation Associated With Dementia Who Require at Leastmoderate to Full Assistance With Activities of Daily Living $748,660 3 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of Bxcl501 Over A 12 Week Treatment Period in Subjects With Agitation Associated With Dementia Who Require at Least Moderate to Full Assistance With Activities of Daily Living $740,551 2 payments
  5. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Ly3451838 in Adults With Treatment-Resistant Migraine $494,903 6 payments
  6. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $406,907 1 payment
  7. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $298,007 6 payments
  8. Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine $263,517 22 payments
  9. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $179,196 2 payments
  10. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $179,088 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record